TopFunds

West Pharmaceutical Services

NYSE: WST

Stock price

363.27 USD

(+0%) TODAY

Health Care SuppliesMedical - Instruments & Supplies
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1.3
1.9
2
2.7
3.2
4.6
8.7
7.7
7.9
6.7
6.8
18%
02Free cash flow per share
1.1
0.7
1.7
2.4
3.2
3.9
4.3
5.8
5.5
3.8
6.4
19.4%
03Dividends per share
0.5
0.5
0.5
0.6
0.6
0.7
0.7
0.7
0.8
0.8
0.9
6.6%
04Dividends payout, %
33.9%
24.9%
26%
20.4%
18.7%
13.9%
7.7%
9.2%
9.6%
12%
12.4%
(9.6)%
PROFIT AND LOSS STATEMENT
05Revenue
1,398
1,509
1,600
1,718
1,844
2,147
2,831
2,886
2,951
2,893
3,074
8.2%
06% Change
-
-
-
-
-
-
-
-
-
-
-
8.2%
07Cost of revenue
(943.9)
(1,008)
(1,085)
(1,172)
(1,235)
(1,379)
(1,657)
(1,747)
(1,818)
(1,891)
(1,970)
7.6%
08Gross profit
454.1
501
514.8
546.3
608.8
767.9
1,173
1,139
1,133
1,002
1,103
9.3%
09% Margin
32.5%
33.2%
32.2%
31.8%
33%
35.8%
41.5%
39.5%
38.4%
34.7%
35.9%
35.3% A
10Operating expenses
(328.4)
(285.5)
(285.1)
(291.5)
(311.6)
(348.9)
(414.7)
(375.4)
(421.8)
(407.6)
(485.9)
4%
11% of Revenue
(23.5)%
(18.9)%
(17.8)%
(17)%
(16.9)%
(16.3)%
(14.7)%
(13)%
(14.3)%
(14.1)%
(15.8)%
(16.6)% A
12Operating Income
125.7
215.5
229.7
254.8
297.2
419
758.7
763.5
710.9
594.6
617.4
17.3%
13Income tax expense
(26.3)
(54.4)
(80.9)
(41.4)
(59)
(72.5)
(107.2)
(114.7)
(122.3)
(107.5)
(121.6)
16.6%
14Net Income
95.6
143.6
150.7
206.9
241.7
346.2
661.8
585.9
593.4
492.7
493.7
17.8%
15% Margin
6.8%
9.5%
9.4%
12%
13.1%
16.1%
23.4%
20.3%
20.1%
17%
16.1%
14.9% A
16Shares Outstanding
73.8
75
75.8
75.4
75.4
75.8
76.3
75.8
75.3
73.7
72.7
(0.2)%
17EPS Basic
1.3
2
2
2.8
3.3
4.7
8.9
7.9
8
6.8
6.8
17.8%
18EPS Diluted
1.3
1.9
2
2.7
3.2
4.6
8.7
7.7
7.9
6.7
6.8
18%
19EBITDA
217.7
286.9
326.2
353.2
403.2
518.9
879.7
808.1
844.1
743.8
723.6
12.8%
% Margin
15.6%
19%
20.4%
20.6%
21.9%
24.2%
31.1%
28%
28.6%
25.7%
23.5%
23.5% A
20Net Interest Income (expense)
(10.1)
(5.3)
(5.8)
(6)
(4.2)
(7.1)
(7.5)
(2.5)
19.2
16.7
17.1
-
21Net Debt / EBITDA
0.1
0.1
(0.1)
(0.4)
(0.3)
(0.6)
(0.5)
(0.7)
(0.6)
(0.2)
(0.5)
(0.3) A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
274.6
203
235.9
337.4
439.1
615.5
762.6
894.3
853.9
484.6
791.3
11.2%
23Short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
181.4
200.5
253.2
288.2
319.3
385.3
489
507.4
512
552.5
574.4
12.2%
25Other current assets
36.6
39.1
39.2
54.3
64.6
51.6
112
103
135.8
124
168.6
16.5%
26Inventory
181.1
199.3
215.2
214.5
235.7
321.3
378.4
414.8
434.7
377
443.9
9.4%
27Total Current Assets
673.7
641.9
743.5
894.4
1,059
1,374
1,742
1,920
1,936
1,538
1,978
11.4%
Non-Current Assets
28Net property, plant & equipment
721
778.3
855
822
909.4
1,012
1,127
1,263
1,513
1,686
1,843
9.8%
29Long-term investments
61.3
82.7
85.8
91.2
192.7
214.7
207.7
204.9
210
202.1
212.3
13.2%
30Other non-current assets
239.1
213.8
178.5
171.4
180.6
193.9
237.3
229.7
170.6
217.2
236.2
(0.1)%
31Total Non-Current Assets
1,021
1,075
1,119
1,085
1,283
1,420
1,572
1,697
1,893
2,105
2,292
8.4%
Total Assets
1,695
1,717
1,863
1,592
2,341
2,794
3,314
3,617
3,830
3,643
4,270
9.7%
LIABILITIES
Current Liabilities
32Accounts payable
119.8
122
138.1
130.4
156.8
213.1
232.2
215.4
242.4
239.3
253.7
7.8%
33Short-term debt
69.3
2.4
-
0.1
11.9
12.4
53.5
18.2
151.7
18.8
22.7
(10.6)%
34Other current liabilities
125.2
116.6
141.4
153.2
172.9
277.9
308.4
285.4
277.7
292.3
378.5
11.7%
35Total Current Liabilities
314.3
241
279.5
283.7
341.6
503.4
594.1
519
671.8
550.4
654.9
7.6%
Non-Current Liabilities
36Long-term debt
228.9
226.2
197
196
317.4
313.3
271.8
299.7
157.3
286.5
394
5.6%
37Other non-current liabilities
128
132
106.4
102.9
109.2
122.6
112.5
113.2
119.4
124.2
45.1
(9.9)%
38Total Non-Current Liabilities
356.9
358.2
303.4
298.9
426.6
435.9
384.3
412.9
276.7
410.7
439.1
2.1%
39Total Liabilities
671.2
599.2
582.9
582.6
768.2
939.3
978.4
931.9
948.5
961.1
1,094
5%
SHAREHOLDERS` EQUITY
40Common stock
18.1
18.4
18.8
18.8
18.8
18.8
18.8
18.8
18.8
18.8
18.8
0.4%
41Retained earnings / (deficit)
964.6
1,072
1,178
1,353
1,549
1,847
2,457
2,988
3,523
3,957
4,375
16.3%
42Accumulated other comprehensive income / (loss)
(162.6)
(186.8)
(117.3)
(154.2)
(149.6)
(110.6)
(159.6)
(183)
(143.8)
(258.1)
(105.5)
(4.2)%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
1,024
1,118
1,280
1,396
1,573
1,855
2,335
2,685
2,881
2,682
3,176
12%
45Total Liabilities and shareholders' Equity
1,695
1,717
1,863
1,592
2,341
2,794
3,314
3,617
3,830
3,643
4,270
9.7%
46Total Debt
298.2
228.6
197
196.1
329.3
325.7
325.3
317.9
309
305.3
416.7
3.4%
47Net Debt
23.6
25.6
(38.9)
(141.3)
(109.8)
(289.8)
(437.3)
(576.4)
(544.9)
(179.3)
(374.6)
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
95.6
143.6
150.7
206.9
241.7
346.2
661.8
585.9
593.4
492.7
493.7
17.8%
49Depreciation & amortization
89.9
90.7
96.7
104.4
103.4
109.1
122.3
120.6
137.3
155.4
168.6
6.5%
50Share-based compensation expense
29.6
19.5
16.1
15.1
24.4
34
37.5
23.7
23.3
18.7
23.8
(2.2)%
51Changes in working capital and other assets
(2.7)
(34.4)
(0.2)
(37.8)
(2.3)
(16.8)
(237.6)
(6.2)
22.5
(13.4)
68.7
-
52Net cash flows from operating activities
212.4
219.4
263.3
288.6
367.2
472.5
584
724
776.5
653.4
754.8
13.5%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(131.6)
(170.2)
(130.8)
(104.7)
(126.4)
(174.4)
(253.4)
(284.6)
(362)
(377)
(285.9)
8.1%
54Purchases of investments / marketable securities
-
(8.4)
-
-
(85.1)
-
-
-
-
-
-
116.4%
55Proceeds from maturities of marketable securities
-
-
-
-
85.1
-
-
-
-
-
-
-
56Other investing activities
2.1
2.8
(2.8)
3.9
(101.6)
(5.1)
0.3
(3.6)
(6.7)
(1.7)
-
-
57Net cash flows from investing activities
(129.5)
(175.8)
(133.6)
(100.8)
(228)
(179.5)
(253.1)
(288.2)
(368.7)
(378.7)
(285.9)
8.2%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(5.6)
(55.9)
(74.4)
(70.8)
(85.3)
(121.4)
(151.9)
(222.2)
(451.2)
(566.6)
(115.8)
35.4%
59Dividends paid, net
(32.4)
(35.8)
(39.1)
(42.1)
(45.1)
(48.1)
(51.1)
(54.1)
(57)
(59.1)
(61.2)
6.6%
60Debt issuance (repayments), net
(27.4)
(69.8)
(34.9)
(0.1)
62.1
(2.3)
(2.2)
(44.3)
(2.3)
(27.6)
(1.1)
(27.5)%
61Other financing activities
23.9
47.6
39.4
32.3
31.5
34.7
37.1
27
50.9
30.7
(7)
-
62Net cash flows from financing activities
(41.5)
(113.9)
(109)
(80.7)
(36.8)
(137.1)
(168.1)
(293.6)
(459.6)
(622.6)
(185.1)
16.1%
63Increase (decrease) in cash and cash equivalents
19.3
(71.6)
32.9
101.5
101.7
176.4
147.1
131.7
(40.4)
(369.3)
306.7
31.9%
64Cash and equivalents, ending balance
274.6
203
235.9
337.4
439.1
615.5
762.6
894.3
853.9
484.6
791.3
11.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
80.8
49.2
132.5
183.9
240.8
298.1
330.6
439.4
414.5
276.4
468.9
19.2%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

West Pharmaceutical Services (WST) financial statements and performance

Explore West Pharmaceutical Services (WST) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.